Chief Executive of Vectura Group to step down

Chris Blackwell will leave the company on 30 June 2015

After 12 years with Vectura, a UK-based developer of products to treat airways related diseases such as asthma and chronic obstructive pulmonary disease (COPD), Chris Blackwell will step down as Chief Executive on 30 June.

Blackwell, who joined the company before the Initial Public Offering (IPO) and will assist the Board in the search for his successor, feels that 'now is the right time to move on'.

You may also like

Drug Delivery

Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Research & Development

Vectura partners with Monash University on inhaled oxytocin

The inhalation formula will be used instead of the current injection method
Drug Delivery

Vectura and Propeller Health link up to develop digitally-connected inhalers for chronic respiratory diseases

The two firms are also discussing additional connected strategies for other proprietary respiratory devices in Vectura’s pipeline
Research & Development

Vectura and UCB form inflammatory disease collaboration

Will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Subscribe now